(Q44258171)

1 December 2017

title

Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis (English)

1 reference

1 December 2017

0 references

1 reference

D S Goodin

1

1 reference

1 December 2017

B Hurwitz

series ordinal

2

1 reference

1 December 2017

A Noronha

series ordinal

3

1 reference

1 December 2017

publication date

1 March 2007

1 reference

Journal of International Medical Research

1 December 2017

published in

1 reference

1 December 2017

volume

35

1 reference

1 December 2017

issue

2

1 reference

1 December 2017

page(s)

173-187

1 reference

Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500202

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500202

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500202

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500202

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500202

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500202

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500202

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500202

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500202

Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500202

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500202

The clinical impact of interferon beta antibodies in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500202

A novel sensitive and selective bioassay for human type I interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500202

Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500202

Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500202

Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500202

Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis--results of a retrospective multicenter observational study over five years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500202

Efecto a largo plazo de los anticuerpos neutralizantes de interferón beta-1 b en pacientes con esclerosis múltiple

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500202

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500202

10.1177/147323000703500202

21 January 2018

Identifiers

DOI

1 reference

1 December 2017

1 reference